BIO on the American Road in Puerto Rico: ‘Medicine Cabinet’ Ready to Reshore

Why It Matters

Puerto Rico’s biotech resurgence strengthens U.S. supply‑chain resilience and creates high‑value jobs, positioning the island as a strategic reshoring hub. The influx of capital also boosts the island’s broader economic recovery after fiscal and natural‑disaster setbacks.

Key Takeaways

• Puerto Rico exports nearly 20% of U.S. drug shipments
• Amgen invests $650M, total $5B on island
• Eli Lilly adds $1.2B biotech expansion
• Biotech sector provides 94k jobs, 150k with induced
• 50% R&D tax credit attracts reshoring firms

Pulse Analysis

Puerto Rico’s biotech ecosystem has evolved from a legacy manufacturing base into a modern reshoring destination. The island’s competitive advantages—highly skilled bilingual workforce, FDA jurisdiction, and a dense network of pharmaceutical firms—have attracted marquee investments from Amgen and Eli Lilly. These projects not only expand production capacity but also embed advanced manufacturing technologies, reinforcing supply‑chain resilience for critical medicines across the United States and beyond.

Government policy plays a pivotal role in sustaining this momentum. The 2025 executive order on reshoring, coupled with the island’s 50% research‑and‑development tax credit, creates a fiscal environment that rivals any U.S. state. Initiatives such as the Puerto Rico Science, Technology & Research Trust’s biotech incubator and the PR BioTech Hub streamline clinical trials and commercialization, further lowering barriers for startups and multinational firms seeking a foothold in the Americas.

Academic partnerships amplify the talent pipeline essential for long‑term growth. The University of Puerto Rico’s Molecular Sciences Research Center, along with programs like Amgen’s Biotech Experience and BioTalents, cultivates a pipeline of scientists and engineers ready to staff high‑tech facilities. By aligning education, industry, and government, Puerto Rico is not only preserving its status as the nation’s top pharmaceutical exporter but also positioning itself as a strategic hub for future biotech innovation and reshoring initiatives.